These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1554 related articles for article (PubMed ID: 29096949)

  • 1. Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial.
    Colombel JF; Panaccione R; Bossuyt P; Lukas M; Baert F; Vaňásek T; Danalioglu A; Novacek G; Armuzzi A; Hébuterne X; Travis S; Danese S; Reinisch W; Sandborn WJ; Rutgeerts P; Hommes D; Schreiber S; Neimark E; Huang B; Zhou Q; Mendez P; Petersson J; Wallace K; Robinson AM; Thakkar RB; D'Haens G
    Lancet; 2017 Dec; 390(10114):2779-2789. PubMed ID: 29096949
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of BI 695501 versus adalimumab reference product in patients with advanced Crohn's disease (VOLTAIRE-CD): a multicentre, randomised, double-blind, phase 3 trial.
    Hanauer S; Liedert B; Balser S; Brockstedt E; Moschetti V; Schreiber S
    Lancet Gastroenterol Hepatol; 2021 Oct; 6(10):816-825. PubMed ID: 34388360
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treat to target versus standard of care for patients with Crohn's disease treated with ustekinumab (STARDUST): an open-label, multicentre, randomised phase 3b trial.
    Danese S; Vermeire S; D'Haens G; Panés J; Dignass A; Magro F; Nazar M; Le Bars M; Lahaye M; Ni L; Bravata I; Lavie F; Daperno M; Lukáš M; Armuzzi A; Löwenberg M; Gaya DR; Peyrin-Biroulet L;
    Lancet Gastroenterol Hepatol; 2022 Apr; 7(4):294-306. PubMed ID: 35120656
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased versus conventional adalimumab dose interval for patients with Crohn's disease in stable remission (LADI): a pragmatic, open-label, non-inferiority, randomised controlled trial.
    van Linschoten RCA; Jansen FM; Pauwels RWM; Smits LJT; Atsma F; Kievit W; de Jong DJ; de Vries AC; Boekema PJ; West RL; Bodelier AGL; Gisbertz IAM; Wolfhagen FHJ; Römkens TEH; Lutgens MWMD; van Bodegraven AA; Oldenburg B; Pierik MJ; Russel MGVM; de Boer NK; Mallant-Hent RC; Ter Borg PCJ; van der Meulen-de Jong AE; Jansen JM; Jansen SV; Tan ACITL; van der Woude CJ; Hoentjen F;
    Lancet Gastroenterol Hepatol; 2023 Apr; 8(4):343-355. PubMed ID: 36736339
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risankizumab in patients with moderate to severe Crohn's disease: an open-label extension study.
    Feagan BG; Panés J; Ferrante M; Kaser A; D'Haens GR; Sandborn WJ; Louis E; Neurath MF; Franchimont D; Dewit O; Seidler U; Kim KJ; Selinger C; Padula SJ; Herichova I; Robinson AM; Wallace K; Zhao J; Minocha M; Othman AA; Soaita A; Visvanathan S; Hall DB; Böcher WO
    Lancet Gastroenterol Hepatol; 2018 Oct; 3(10):671-680. PubMed ID: 30056030
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Etrolizumab as induction and maintenance therapy in patients with moderately to severely active Crohn's disease (BERGAMOT): a randomised, placebo-controlled, double-blind, phase 3 trial.
    Sandborn WJ; Panés J; Danese S; Sharafali Z; Hassanali A; Jacob-Moffatt R; Eden C; Daperno M; Valentine JF; Laharie D; Baía C; Atreya R; Panaccione R; Rydzewska G; Aguilar H; Vermeire S;
    Lancet Gastroenterol Hepatol; 2023 Jan; 8(1):43-55. PubMed ID: 36240801
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intensive drug therapy versus standard drug therapy for symptomatic intestinal Crohn's disease strictures (STRIDENT): an open-label, single-centre, randomised controlled trial.
    Schulberg JD; Wright EK; Holt BA; Hamilton AL; Sutherland TR; Ross AL; Vogrin S; Miller AM; Connell WC; Lust M; Ding NS; Moore GT; Bell SJ; Shelton E; Christensen B; De Cruz P; Rong YJ; Kamm MA
    Lancet Gastroenterol Hepatol; 2022 Apr; 7(4):318-331. PubMed ID: 34890567
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adalimumab for maintenance of remission in Crohn's disease.
    Townsend CM; Nguyen TM; Cepek J; Abbass M; Parker CE; MacDonald JK; Khanna R; Jairath V; Feagan BG
    Cochrane Database Syst Rev; 2020 May; 5(5):CD012877. PubMed ID: 32413933
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study.
    Feagan BG; Sandborn WJ; D'Haens G; Panés J; Kaser A; Ferrante M; Louis E; Franchimont D; Dewit O; Seidler U; Kim KJ; Neurath MF; Schreiber S; Scholl P; Pamulapati C; Lalovic B; Visvanathan S; Padula SJ; Herichova I; Soaita A; Hall DB; Böcher WO
    Lancet; 2017 Apr; 389(10080):1699-1709. PubMed ID: 28411872
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn's disease: a systematic review and network meta-analysis.
    Singh S; Murad MH; Fumery M; Sedano R; Jairath V; Panaccione R; Sandborn WJ; Ma C
    Lancet Gastroenterol Hepatol; 2021 Dec; 6(12):1002-1014. PubMed ID: 34688373
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study.
    Kennedy NA; Heap GA; Green HD; Hamilton B; Bewshea C; Walker GJ; Thomas A; Nice R; Perry MH; Bouri S; Chanchlani N; Heerasing NM; Hendy P; Lin S; Gaya DR; Cummings JRF; Selinger CP; Lees CW; Hart AL; Parkes M; Sebastian S; Mansfield JC; Irving PM; Lindsay J; Russell RK; McDonald TJ; McGovern D; Goodhand JR; Ahmad T;
    Lancet Gastroenterol Hepatol; 2019 May; 4(5):341-353. PubMed ID: 30824404
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deep Remission at 1 Year Prevents Progression of Early Crohn's Disease.
    Ungaro RC; Yzet C; Bossuyt P; Baert FJ; Vanasek T; D'Haens GR; Joustra VW; Panaccione R; Novacek G; Reinisch W; Armuzzi A; Golovchenko O; Prymak O; Goldis A; Travis SP; Hébuterne X; Ferrante M; Rogler G; Fumery M; Danese S; Rydzewska G; Pariente B; Hertervig E; Stanciu C; Serrero M; Diculescu M; Peyrin-Biroulet L; Laharie D; Wright JP; Gomollón F; Gubonina I; Schreiber S; Motoya S; Hellström PM; Halfvarson J; Butler JW; Petersson J; Petralia F; Colombel JF
    Gastroenterology; 2020 Jul; 159(1):139-147. PubMed ID: 32224129
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Validation of endoscopic activity scores in patients with Crohn's disease based on a post hoc analysis of data from SONIC.
    Ferrante M; Colombel JF; Sandborn WJ; Reinisch W; Mantzaris GJ; Kornbluth A; Rachmilewitz D; Lichtiger S; D'Haens GR; van der Woude CJ; Danese S; Diamond RH; Oortwijn AF; Tang KL; Miller M; Cornillie F; Rutgeerts PJ;
    Gastroenterology; 2013 Nov; 145(5):978-986.e5. PubMed ID: 23954314
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn's disease (PROFILE): a multicentre, open-label randomised controlled trial.
    Noor NM; Lee JC; Bond S; Dowling F; Brezina B; Patel KV; Ahmad T; Banim PJ; Berrill JW; Cooney R; De La Revilla Negro J; de Silva S; Din S; Durai D; Gordon JN; Irving PM; Johnson M; Kent AJ; Kok KB; Moran GW; Mowat C; Patel P; Probert CS; Raine T; Saich R; Seward A; Sharpstone D; Smith MA; Subramanian S; Upponi SS; Wiles A; Williams HRT; van den Brink GR; Vermeire S; Jairath V; D'Haens GR; McKinney EF; Lyons PA; Lindsay JO; Kennedy NA; Smith KGC; Parkes M;
    Lancet Gastroenterol Hepatol; 2024 May; 9(5):415-427. PubMed ID: 38402895
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tight control for Crohn's disease with adalimumab-based treatment is cost-effective: an economic assessment of the CALM trial.
    Panaccione R; Colombel JF; Travis SPL; Bossuyt P; Baert F; Vaňásek T; Danalıoğlu A; Novacek G; Armuzzi A; Reinisch W; Johnson S; Buessing M; Neimark E; Petersson J; Lee WJ; D'Haens GR
    Gut; 2020 Apr; 69(4):658-664. PubMed ID: 31285357
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of Biomarker Cutoffs and Endoscopic Outcomes in Crohn's Disease: A Post Hoc Analysis From the CALM Study.
    Reinisch W; Panaccione R; Bossuyt P; Baert F; Armuzzi A; Hébuterne X; Travis S; Danese S; Sandborn WJ; Schreiber S; Berg S; Zhou Q; Kligys K; Neimark E; Suleiman AA; D'Haens G; Colombel JF
    Inflamm Bowel Dis; 2020 Sep; 26(10):1562-1571. PubMed ID: 32105310
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low dose naltrexone for induction of remission in Crohn's disease.
    Segal D; Macdonald JK; Chande N
    Cochrane Database Syst Rev; 2014 Feb; (2):CD010410. PubMed ID: 24558033
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: results from the CHARM trial.
    Colombel JF; Sandborn WJ; Rutgeerts P; Kamm MA; Yu AP; Wu EQ; Pollack PF; Lomax KG; Chao J; Mulani PM
    Am J Gastroenterol; 2009 May; 104(5):1170-9. PubMed ID: 19352339
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective study of an adalimumab combined with partial enteral nutrition in the induction period of Crohn's disease.
    Zhou S; Huang Z; Hou W; Lin Y; Yu J
    Inflamm Res; 2024 Feb; 73(2):199-209. PubMed ID: 38168701
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial.
    Sands BE; Irving PM; Hoops T; Izanec JL; Gao LL; Gasink C; Greenspan A; Allez M; Danese S; Hanauer SB; Jairath V; Kuehbacher T; Lewis JD; Loftus EV; Mihaly E; Panaccione R; Scherl E; Shchukina OB; Sandborn WJ;
    Lancet; 2022 Jun; 399(10342):2200-2211. PubMed ID: 35691323
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 78.